Degertekin Bulent, Tozun Nurdan, Soylemez Aysegul Gizem, Gurtay Ezgi, Bozkurt Ugur, Yilmaz Yusuf, Yapali Suna, Vardareli Eser, Unal Hakan Umit, Colakoglu Berkan, Alpaydin Can Berk
Department of Gastroenterology and Hepatology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey.
Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey.
Hepatol Forum. 2020 Sep 21;1(3):88-96. doi: 10.14744/hf.2020.2020.0026. eCollection 2020 Sep.
This study aims to investigate the effects of chronic coffee consumption (>5 years) and type of coffee in non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver (NAFLD) and patients who have regular alcohol consumption.
In this study, 158 healthy individuals and 101 patients with histologically proven NASH were enrolled. The daily amount of coffee intake, amount of alcohol use and type of coffee were calculated for all patients. The degree of steatosis and fibrosis was analyzed by transient elastography and liver ultrasound in non-NASH and by liver biopsy in NASH patients.
Patients with a history of coffee consumption (n=132) had lower liver enzyme levels compared to the non-coffee group (n=127) (p=0.001). Serum ALT level was significantly lower [ALT: 21.2±11.7 U/L vs. 56.4±15.6 U/L (p=0.004)], and the liver histopathology was significantly better for patients with a coffee consumption of daily for >5years (p=0.045 for fibrosis score for NASH, p=0.036 for LSM and p=0.015 for CAP measurements for the non-NASH patient).
Coffee seems to have a positive protective effect on liver histology and liver enzyme levels in healthy individuals, in patients with chronic alcohol consumption, NAFLD and NASH. These results are more prominent in patients who drink coffee on a regular daily base for more than five years.
本研究旨在调查长期饮用咖啡(超过5年)及咖啡类型对非酒精性脂肪性肝炎(NASH)、非酒精性脂肪肝(NAFLD)以及有规律饮酒患者的影响。
本研究纳入了158名健康个体和101名经组织学证实为NASH的患者。计算了所有患者的每日咖啡摄入量、酒精摄入量及咖啡类型。非NASH患者通过瞬时弹性成像和肝脏超声分析脂肪变性和纤维化程度,NASH患者通过肝活检进行分析。
有咖啡饮用史的患者(n = 132)与无咖啡饮用史的患者(n = 127)相比,肝酶水平较低(p = 0.001)。血清ALT水平显著更低[ALT:21.2±11.7 U/L对56.4±15.6 U/L(p = 0.004)],且每日饮用咖啡超过5年的患者肝脏组织病理学明显更好(NASH患者纤维化评分p = 0.045,非NASH患者LSM p = 0.036,CAP测量p = 0.015)。
咖啡似乎对健康个体、慢性饮酒患者、NAFLD和NASH患者的肝脏组织学和肝酶水平具有积极的保护作用。这些结果在每日规律饮用咖啡超过五年的患者中更为显著。